Alan M Rapoport MD
Headache
Clinical Professor of Neurology, David Geffen School of Medicine at UCLA; Private Practice Neurologist, California Medical Clinic for Headache; Founder and Director-Emeritus of the New England Center for Headache; Founding President of the Headache Cooperative of New England (HCNE) and the Headache Cooerative of the Pacific (HCOP). Past President of the International Headache Society
Join to View Full Profile
317 North Mansfield AvenueLos Angeles, CA 90036
Dr. Rapoport is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Clinical Professor of Neurology at the David Geffen School of Medicine at UCLA in Los Angeles and has a private practice in Beverly Hills, California. He a past president of the International Headache Society, the Founder and Director-Emeritus of the New England Center for Headache in Stamford, Connecticut, and the Founding President of the Headache Cooperative of New England.
Dr. Rapoport has written over 350 articles on headache and Co Authored 9 books for doctors, nurses and patients. He is the CEO and Co-Founder of BonTriage, a medical IT company helping patients to obtain more accurate diagnoses and better outcomes.
Education & Training
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1967 - 1970
Maimonides Medical CenterInternship, Internal Medicine, 1966 - 1967
State University of New York Downstate Medical Center College of MedicineClass of 1966
Certifications & Licensure
CA State Medical License 2004 - 2026
CT State Medical License 1971 - 2009
FL State Medical License 1973 - 2007
NY State Medical License 1967 - 2007
American Board of Psychiatry and Neurology Neurology
UCNSHeadache Medicine
Clinical Trials
- Preventive Treatment of Episodic and Chronic Migraine Start of enrollment: 2011 Apr 01
- Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve Start of enrollment: 2014 Mar 01
Publications & Presentations
PubMed
- Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation.Wanakorn Rattanawong, Prakit Anukoolwittaya, Akarin Hiransuthikul, Thanakit Pongpitakmetha, Auranee Trisataya
The Journal of Headache and Pain. 2025-01-16 - Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study.Stewart J Tepper, Detlef Albrecht, Jessica Ailani, Louis Kirby, Shannon Strom
CNS Drugs. 2024-12-01 - 1 citationsContinuing evolution of migraine-specific therapies - targeting migraine with precision and persistence.Dimos D Mitsikostas, Alan Rapoport
Nature Reviews. Neurology. 2024-11-01
Press Mentions
Medication Underuse Headache Demands Attention, Effective Prevention, and Timely TreatmentDecember 12th, 2024- Erenumab Reduces Nonopioid Medication Overuse Headache in Chronic MigraineOctober 4th, 2024
- Prednisolone May Improve MOH WithdrawalFebruary 13th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
